» Articles » PMID: 16551636

Heavy and Light Chain Variable Single Domains of an Anti-DNA Binding Antibody Hydrolyze Both Double- and Single-stranded DNAs Without Sequence Specificity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2006 Mar 23
PMID 16551636
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-DNA antibodies (Abs) are of biomedical interest because they are associated with autoimmune diseases in human and mice. Previously we isolated an anti-DNA monoclonal Ab 3D8 from an autoimmune-prone MRL-lpr/lpr mouse. Here we have characterized DNA binding kinetics and hydrolyzing activities of the recombinant single chain variable fragment (scFv) and the single variable domains of heavy chain (VH) and light chain (VL) using various single-stranded (ss) and double-stranded (ds) DNA substrates. All the Abs bound to both ds- and ssDNAs without significant preferential sequence specificity showing scFv higher affinities (KD = approximately 17-74 nm) than VH (KD = approximately 2.4-8.4 microm) and VL (KD = approximately 3.2-72 microm), and efficiently hydrolyzed both ds- and ssDNAs without sequence specificity in a Mg2+-dependent manner, except for the poor activity of 3D8 scFv for ss-(dT)40. Elucidated crystal structure-based His to Ala mutations on the complementarity determining regions of VH (His-H35 --> Ala) and/or VL (His-L94 --> Ala) of 3D8 scFv significantly inhibited the catalytic activities, indicating that the His residues are involved in the catalytic mechanism of 3D8 scFv. However, the DNA hydrolyzing activities of single domain VH and VL were not affected by the mutations, indicative of their different catalytic mechanisms from that of 3D8 scFv. Our results demonstrate single domain Abs with DNase activities for the first time, which might provide new insights into substrate recognition and catalytic mechanisms of anti-DNA Abs.

Citing Articles

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.

Luong Q, Hoang P, Ho P, Ayun R, Lee T, Lee S Int J Mol Sci. 2025; 26(4).

PMID: 40003946 PMC: 11855616. DOI: 10.3390/ijms26041481.


Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies.

Hifumi E, Ito Y, Tsujita M, Taguchi H, Uda T Sci Rep. 2024; 14(1):12184.

PMID: 38806597 PMC: 11133420. DOI: 10.1038/s41598-024-63116-6.


A synergistic therapy against influenza virus A/H1N1/PR8 by a HA1 specific neutralizing single-domain V and an RNA hydrolyzing scFv.

Hoang P, Luong Q, Ayun R, Lee Y, Oh K, Kim T Front Microbiol. 2024; 15:1355599.

PMID: 38706966 PMC: 11066198. DOI: 10.3389/fmicb.2024.1355599.


An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models.

Luong Q, Hoang P, Lee Y, Ayun R, Na K, Park S Sci Rep. 2024; 14(1):8472.

PMID: 38605110 PMC: 11009316. DOI: 10.1038/s41598-024-52810-0.


Some structural features of the peptide profile of myelin basic protein-hydrolyzing antibodies in schizophrenic patients.

Zavialova M, Kamaeva D, Kazieva L, Skvortsov V, Smirnova L PeerJ. 2023; 11:e15584.

PMID: 37431466 PMC: 10329820. DOI: 10.7717/peerj.15584.